Skip to main content

Table 1 Demographics and clinical characteristics of 10 patients with BRAF mutation- positive melanoma

From: Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Variable Group No. of patients %
(n = 10)
Age, years Median 52  
  Range 23-60  
  <50 5 50
  ≥50 5 50
Sex Men 7 70
  Women 3 30
Race Caucasian 10 100
Number of prior therapies Median 2  
  Range 0-5  
  ≤2 8 80
  >2 2 20
Lactate dehydrogenasea ≤upper limit of normal 9 90
  >upper limit of normal 1 10
TNM stage M1c No 6 60
  Yes 4 40
ECOG PS 0 5 50
  1 5 50
Therapy BRAF inhibitor alone 7 70
  MEK inhibitor alone 1 10
  BRAF/MEK inhibitor combination 2 20
Treatment response Complete response 4 40
  Partial response 6 60
  1. aUpper limit of normal in our institution = 618 IU/L.
  2. Abbreviations:ECOG Eastern Cooperative Oncology Group, PS Performance Status, TNM tumor, node, metastasis.